RA Capital

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Ajax Therapeutics is a New York City-based biotechnology company that applies computational chemistry and structure-based technologies to develop novel small molecules for treating hematologic malignancies.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

Sortera Alloys manufactures low-cost, high-quality metal alloys for domestic manufacturing using its artificial intelligence technology. Sortera Alloys is a company based in Fort Wayne, Indiana, and was established in 2020.

Spyglass Pharma specializes in developing innovative treatments for chronic eye diseases using advanced technologies. The company aims to deliver multiple drugs to address additional ophthalmic indications.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing innovative drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company employs a unique implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of valproic acid, an anti-epileptic drug formulated as CT-010. By utilizing reformulated off-patent drugs delivered directly to the brain's ventricles, Cerebral Therapeutics aims to bypass the blood-brain barrier, thereby enhancing treatment outcomes for patients suffering from chronic neurological conditions. Established in 2010, the company is committed to improving the quality of life for those with uncontrolled neurological disorders.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Exo is a medical device startup specializing in handheld ultrasound technology. It combines advanced materials, sensors, signal processing, and computation with semiconductor manufacturing economies to deliver affordable, high-quality imaging. This empowers healthcare professionals to make critical real-time decisions, enhancing patient outcomes.

Element Biosciences develops innovative genetic analysis tools for research and diagnostic markets. Founded in 2017, the company specializes in a disruptive DNA sequencing technology that offers high-quality data, workflow flexibility, and affordable access to next-generation sequencing.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Ceribell designs and manufactures medical devices for acquiring and interpreting electroencephalography (EEG) data in patients with various neurological conditions. Its flagship product, the Ceribell EEG System, includes a headband that accommodates diverse hair types and head sizes, along with a pocket-sized recorder offering clinical quality EEG and on-device display. The system enables healthcare providers to set up EEG monitoring in just six minutes, with a proprietary Brain Stethoscope function converting brainwaves into sound for easier detection of seizures.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Tenaya Therapeutics is a preclinical-stage biotechnology company focused on developing therapies for heart disease and heart failure. It operates three product platforms: cellular regeneration, which aims to regenerate heart tissue by reprogramming cardiac fibroblasts into cardiomyocytes via delivery of proprietary transcription factors; gene therapy, which targets cardiac fibroblasts to deliver therapeutic payloads; and precision medicine, which enables personalized approaches to treat heart disease. Founded in 2016 and headquartered in South San Francisco, California, Tenaya seeks to address the underlying cellular pathologies of diseased myocardium with curative therapies that advance from discovery through development.

Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative therapeutics to address significant unmet medical needs. Established in 2013, Vividion utilizes a pioneering platform for proteome-wide small molecule drug discovery, which combines advanced synthetic chemistry techniques with chemical proteomics. This approach allows the company to expand the druggable proteome and target challenging proteins, ultimately enabling the discovery of transformative treatments for serious illnesses. Vividion's scientific foundation stems from experts in chemical biology and synthetic chemistry at The Scripps Research Institute, reflecting its commitment to advancing therapeutics that can significantly improve patient outcomes.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

TScan Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing T cell receptor (TCR) engineered T cell therapies for cancer treatment. Its primary focus is on liquid tumors, with lead therapy candidates TSC-100 and TSC-101 aimed at addressing hematologic malignancies by targeting residual leukemia and preventing relapse following hematopoietic stem cell transplantation. In addition to its liquid tumor programs, TScan is advancing multiplexed TCR-T therapy candidates to tackle various solid tumors. The company employs a unique platform that identifies previously uncharacterized shared T cell antigens and assesses off-target TCR interactions, which supports the creation of TCR-T therapies with reduced off-target effects. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan Therapeutics aims to transform cancer treatment through innovative T cell therapies.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Founded in 2014, Vivace Therapeutics is a biotechnology company based in the San Francisco Bay Area. It focuses on discovering and developing cancer therapeutics by targeting novel pathways, with a particular emphasis on the Hippo pathway which controls tissue regeneration and organ size.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for severe, rare muscle disorders with significant unmet medical need. It employs a holistic drug discovery approach targeting the muscle as an organ, utilizing its proprietary platform to identify precision medicines regulating key proteins in muscle tissue.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Kinnate Biopharma Inc. is a biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating genomically defined cancers. Established in 2018 and headquartered in San Diego, California, the company focuses on precision oncology therapeutics, leveraging its expertise in structure-based drug discovery and translational research. Kinnate's lead product candidate, KIN002787, is a rapidly accelerated fibrosarcoma inhibitor currently in preclinical development for lung cancer, melanoma, and other solid tumors. Additionally, the company is advancing other preclinical candidates, including KIN003, which targets cancer-associated alterations in FGFR2 and FGFR3 genes, and a Cyclin-Dependent Kinase 12 inhibitor in the KIN004 program. Kinnate Biopharma is committed to developing targeted therapeutics for underserved patient populations, aiming to expand the reach of precision medicine in cancer treatment.

Bolt Biotherapeutics is a biotechnology company developing cancer immunotherapies based on the Boltbody platform, which links tumor-targeting antibodies to immune-stimulating payloads to activate innate and adaptive immune responses against solid tumors. The platform aims to transform non-responsive, or cold, tumors into immunologically active ones by delivering immune stimulants at the tumor site. The company’s pipeline includes BDC-1001 as a monotherapy for HER2-expressing solid tumors, with additional candidates such as BDC-3042 and Next-Gen ISAC designed to broaden its immuno-oncology program. Bolt Biotherapeutics focuses on myeloid biology and tumor-targeted therapies to leverage immune mechanisms for cancer treatment.

Everest Medicines is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for critical unmet medical needs, initially focusing on Asia Pacific markets.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Black Diamond Therapeutics discovers and develops small molecule therapies for precision oncology. It focuses on allosteric mutations in kinases related to cancer, with a lead product candidate targeting non-canonical ErbB kinase mutations.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Sojournix Inc., established in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for women's health and neuroendocrine disorders. Its primary focus is SJX-653, a selective neurokinin-3 (NK3) antagonist, designed as a non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause.

Orchard Therapeutics is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative gene therapies for rare diseases. Its core focus is autologous ex vivo gene therapy, transforming hematopoietic stem cells into a gene-modified drug product for single-administration treatments. The company's portfolio includes Strimvelis, approved by the EMA in 2016, and several programs in advanced registrational studies across various disease areas.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

Synthorx, Inc. is a biopharmaceutical company specializing in the development of innovative protein therapeutics using advanced synthetic biology techniques. Founded in 2014 and headquartered in La Jolla, California, Synthorx focuses on its proprietary Synthorin programs aimed at treating cancer and autoimmune disorders. Its lead product candidate, THOR-707, is a modified form of recombinant human IL-2, currently being evaluated for various solid tumors both as a standalone treatment and in combination with immune checkpoint inhibitors. The company also develops Synthorins targeting IL-2 for autoimmune conditions, IL-10 for immuno-oncology applications, and IL-15 for regulating immune responses. Synthorx leverages a unique platform that enables the incorporation of synthetic DNA base pairs to enhance the specificity and efficacy of its protein therapeutics, thus offering improved treatment options for patients. Previously known as Alinos, Inc., the company acquired exclusive rights to its synthetic biology technology based on groundbreaking research from The Scripps Research Institute. As of January 2020, Synthorx operates as a subsidiary of Sanofi.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Spero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Its primary focus is on tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adult use in treating MDR Gram-negative infections.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

ShockWave Medical is a medical device company focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque in peripheral vascular, coronary vascular, and valvular diseases. The company markets lithoplasty catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee lesions, designed to modify calcium and improve vessel compliance before angioplasty or stent delivery. Its sonic pressure wave technology aims to limit injury to healthy tissue and facilitate procedures such as transcatheter coronary interventions and valve therapies. The business serves interventional cardiologists, vascular surgeons, and interventional radiologists through a direct sales force and distributors. It operates in the United States, Germany, the rest of Europe, and other international markets. Founded in 2009, ShockWave Medical is headquartered in Santa Clara, California.

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development, and commercialization of small molecule therapeutics for cancer treatment. The company is advancing several key drug candidates, including trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor currently in Phase 1b/2 clinical trials for extensive-stage small cell lung cancer and Phase 2 trials for first-line small cell lung cancer and metastatic triple-negative breast cancer. Additionally, G1 is developing lerociclib, an oral CDK4/6 inhibitor in Phase 1b/2a trials for breast cancer and Phase 1b trials for non-small cell lung cancer, as well as rintodestrant, an oral selective estrogen receptor degrader in Phase I/2 trials. The company collaborates with Quantum Leap Healthcare Collaborative to explore trilaciclib's potential in neoadjuvant treatment for locally advanced breast cancer. Founded in 2008, G1 Therapeutics aims to address unmet medical needs in oncology by enhancing the effectiveness of existing cancer therapies.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Protagonist Therapeutics, Inc., established in 2006 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies to address unmet medical needs in hematology and gastroenterology. The company's pipeline includes PTG-300, an injectable hepcidin mimetic in Phase II trials for beta-thalassemia; PTG-200, a completed Phase I antagonist peptide candidate for moderate-to-severe Crohn’s disease; and PN-943, an oral integrin antagonist in Phase I trials for inflammatory bowel disease. Protagonist has a licensing and collaboration agreement with Janssen Biotech for PTG-200's development and commercialization. The company's proprietary platform enables the discovery of novel constrained peptide-based drug candidates targeting protein-protein interactions.

Merus is a clinical-stage immuno-oncology company focused on discovering and developing bispecific antibody therapeutics. It utilizes Oligoclonics technology to produce mixtures of human therapeutic antibodies directed to a common antigen from a single cell clone and develops full-length multispecific antibodies known as Biclonics. Merus' pipeline includes bispecific programmes such as MCLA-128, MCLA-117 and MCLA-158, reflecting its emphasis on targeted immune engagement in cancer.

Blueprint Medicines is a Cambridge, Massachusetts-based biopharmaceutical company that develops targeted, small-molecule therapies to treat genomically defined cancers, rare diseases, and related conditions. The company focuses on precision medicines that address molecular drivers and resistance mechanisms, advancing a pipeline that includes avapritinib for systemic mastocytosis and certain gastrointestinal stromal tumors, BLU-263, a KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders, fisogatinib for advanced hepatocellular carcinoma, and pralsetinib, a RET inhibitor for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. It is also pursuing BLU-782, an ALK2 inhibitor in early clinical trials for fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with partner companies such as Clementia Pharmaceuticals, CStone Pharmaceuticals, Genentech, and Hoffmann-La Roche. Founded in 2008, the company operates in the United States and Europe and combines its Insights-to-Validation platform with a proprietary chemical library to discover and develop new therapeutic compounds and combination therapies in oncology, hematology, and related areas.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, dedicated to the development of novel cellular immunotherapies for treating various cancers, including hematological malignancies and solid tumors. The company is advancing its innovative product candidates, notably BPX-601, an autologous GoCAR-T therapy targeting solid tumors that express prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy aimed at tumors expressing human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control over immune system components, enhancing the efficacy and duration of therapeutic responses. Founded in 2004, Bellicum Pharmaceuticals has established collaborations with several organizations to further its research and development efforts in immunotherapy.

Civitas Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative pulmonary delivery therapies aimed at treating central nervous system and respiratory disorders. Utilizing its proprietary ARCUS technology, Civitas aims to transform the therapeutic landscape for patients across the United States. The company's focus is on creating effective treatments that enhance patient outcomes and address unmet medical needs in these critical areas.

Coherus Biosciences is a biopharmaceutical company focused on developing, manufacturing, and commercializing biologic therapeutics for oncology and inflammatory diseases. Its pipeline includes biosimilars for immunology, ophthalmology, and oncology.

ZipLine Medical, Inc. is a medical device company that specializes in developing and marketing non-invasive skin closure solutions. Founded in 2007 and based in Campbell, California, the company focuses on its flagship product, the Zip Surgical Skin Closure, which is designed for use across various medical specialties, including cardiology, orthopedics, and emergency medicine. Utilizing its innovative PRELOC technology platform, ZipLine Medical provides a method for rapid skin closure that combines the speed of staples with the aesthetic benefits of sutures, while minimizing the risk of surgical site infections and reducing scar-promoting tension. This technology aims to enhance surgical outcomes by delivering uniform closure forces along incisions, making it applicable to a wide range of surgical procedures. ZipLine Medical operates as a subsidiary of Stryker Corporation.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

T2 Biosystems, Inc. is an in vitro diagnostics company specializing in the rapid detection of pathogens and biomarkers to enhance patient care. The company employs its proprietary T2 Magnetic Resonance technology, which allows for the detection of various pathogens directly from unpurified patient samples, such as whole blood and urine, without the need for extensive sample preparation. T2 Biosystems offers several diagnostic products, including the T2Dx Instrument, which is designed to identify pathogens associated with sepsis and Lyme disease. Its product lineup includes the T2Candida Panel for detecting Candida species, the T2Bacteria Panel for identifying bacterial pathogens, the T2SARS-CoV-2 Panel for COVID-19 testing, and the T2Resistance Panel for detecting antibiotic resistance markers. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems aims to improve clinical outcomes and reduce healthcare costs by enabling faster and more accurate diagnostic testing.